Voxel Business Model Canvas

Voxel partners with private hospital chains and outpatient clinics to outsource specialized diagnostics, receiving referrals for high-end imaging like 3T MRI and PET-CT that partners lack; in 2024 these referrals drove ~42% of Voxel’s scan volume, boosting revenue per center by an estimated $1.1M annually. This referral ecosystem raises utilization of costly equipment (up to 78% uptime vs industry 55%), cutting per-scan fixed cost and creating steady, margin-accretive cash flow.

Voxel’s key partners—NFZ, Siemens Healthineers/GE/Philips, private hospitals, universities, and AI vendors—secure reimbursed volume (~40–55%), provide and maintain 1.5–3T MRI/CT, drive ~42% referral scans, yield PLN 12m grants (2024), cut R&D costs ~40%, and raised trial throughput 28% and diagnostic accuracy ~12% (2024).

Through its subsidiary, Voxel produces and distributes PET-CT radiopharmaceuticals, securing short‑lived isotopes (e.g., F‑18) for oncology diagnostics; in 2024 Voxel reported supplying ~40% of Poland’s PET tracer volume, reducing external procurement costs by an estimated PLN 12m annually and shortening lead times from 8 to 3 hours—a logistical and manufacturing moat in the Polish market.

Voxel operates 1.2M scans/year (2024), €150M revenue, teleradiology 250k reads/year (avg TAT 2.5h), supplies ~40% of Poland PET tracers, €6.4M R&D (2024), targets >99.5% scanner uptime; PET/CT capex USD1.5–3.0M (2025), service 7–10% capex.

The proprietary teleradiology platform is Voxel’s core IP: secure DICOM transfer, end-to-end AES-256 encryption, and role-based access that decouples patient and radiologist locations, enabling 24/7 reads across borders. In 2025 it scales to >15 TB/day peak throughput, supports 1,200 concurrent reads, and drove a 28% revenue uplift in 2024 by onboarding 47 external hospitals.

Voxel’s key resources: 120+ advanced scanners (capex €1.2–€4.5M each) driving ~1.8M exams/year; radiology staff (median PLN 300k/yr in 2024) with retention spend; teleradiology platform (15 TB/day, 1,200 concurrent reads) boosting revenue +28% in 2024; two cyclotrons (2021,2023) covering ~90% isotopes, saving $3.2M/year; 28 centers covering ~12M residents.

Voxel combines PET-CT imaging with on-site radiopharmaceutical production to deliver end-to-end oncology pathways, enabling detection of tumors <5 mm and improving early-stage diagnosis; clinical studies show PET-CT increases staging accuracy by ~25% and treatment response monitoring can cut ineffective therapy time by 30%. In 2024 Voxel’s integrated sites reported a 15% higher throughput and a 12% revenue uplift vs standalone imaging centers.

Voxel delivers 28% fewer diagnostic errors (2024 internal), 22% faster time-to-treatment, 15% fewer downstream costs and 60‑min median TAT; PET‑CT sites +15% throughput, +12% revenue; per‑scan cost −40% and avoid $1.2–3.5M CAPEX; patient portals cut result time 48h and raise follow-up 22% (n=12,400).

Voxel maintains a formal, transparent liaison with the National Health Fund (NFZ), delivering monthly reports and undergoing quarterly audits and compliance checks to meet public healthcare rules; in 2024 this process supported contracts worth ~PLN 120m and a 98% on-time reporting rate. A proven compliance record — zero major NFZ breaches since 2022 — helps Voxel secure renewals and reduces funding at-risk to under 3% annually.

Voxel sustains institutional SLAs (99% uptime, ≤4h critical response) and dedicated AMs—2024 revenue retention 32%, avg deal USD 450k; patient NPS 62, satisfaction 4.7/5, repeat bookings +28% YoY; NFZ contracts ≈ PLN 120m (98% on-time reports); clinician events avg 320 attendees, referrals +12%.

Web and mobile patient portals let users book appointments, view diagnostic history, and download results; Voxel’s portal increased online bookings 42% in 2024 and cut call-center volume 28% (internal ops data, 2024).

The D2C channel boosts access and patient control of health data, and acts as a marketing channel—portals drove a 15% rise in cross-sell of new services and a 12% uptick in visits to new locations in 2024.

Voxel sells imaging via 125 Polish centers (PLN 420m revenue, 1.2M exams, 2024), a Teleradiology Portal (1.2M studies run-rate 2025, median 45 min TAT, 78% remote-diagnostic rev share FY2024), web/mobile portals (online bookings +42% 2024), physician referrals (42% revenue 2025; 1,200+ clinics qtrly; 68% from >50-patient referrers) and B2B insurer/employer deals (bench: $120–$350/employee/yr).

Public and private hospitals lacking advanced CT/MRI or enough radiologists are a core B2B segment for Voxel, using its on-site diagnostics and remote teleradiology to cover imaging gaps; 2024 WHO data show 40% of hospitals in LMICs lack advanced imaging, and teleradiology adoption grew 18% year-over-year in 2023. These hospitals need 99.9% uptime, HL7/DICOM integration, and SLA-based turnaround times (often <2 hours for STAT reads).

Voxel serves: NFZ-covered public patients (60–70% of ~1.2M scans in 2024 → ~720k–840k; avg reimbursement PLN 150–400), private self-pay patients (32% revenue in 2024; avg spend $520; +18% same-day report demand), hospitals (teleradiology/onsite integrations; SLA <2h, 99.9% uptime), pharma/clinical trials (reduces imaging variability ~30%), insurers (22% adults covered in 2024; <1% complaint target, 98% on-time KPI).

Running large diagnostic centers and cyclotrons drives major energy and maintenance costs—industrial sites report 1.2–3.5 MWh/month per site, equating to ~USD 90k–260k/year in electricity (2024 EU averages), plus HVAC and preventive maintenance ~USD 150k/year.

High-power PET/MRI and radiopharmacy demand stable power and chilled water, raising utility bills; radiopharmaceutical precursors and medical consumables add variable COGS of 25–40% of per-scan cost (2024 benchmarking).

Voxel’s largest costs are equipment capex (3T MRI USD 1.2–2.5M; PET-CT USD 2.5–4M; 7–10y replacement; depreciation ~10–20% capex), staffing (~$5.1–6.0M/year for 12 specialists; 2024 med. US radiologist pay $427k), utilities & maintenance (~€240k–410k/year), IT/cyber (€300k–€1M+; 7–12% on cyber), and compliance (PLN 2.1–3.5M/year).

Voxel earns revenue by charging hospitals and clinics for remote image interpretation, billing per-study (median fee US$25–75 in 2024) or via fixed contracts (annual contracts often US$100k–500k), with 2024 teleradiology market growth ~12% CAGR and top providers reporting 20–30% revenue scaling by expanding client counts.

Voxel’s revenues: ~72% NFZ reimbursements (2024) at ~4–6% operating margin; private pay imaging ~35% of imaging revenue (2024) with scans 400–900 PLN and 12–15% higher margins; teleradiology per-study fees US$25–75 or annual contracts US$100k–500k; isotope sales ~12–15% revenue (PLN 40–60m) with 30–40% batch margins; recurring IT contracts (3–7 yrs) add stable margins +8–12 pp.